Entos, Inc., a San Diego, CA-based creator of a platform combining AI-driven technology and automated synthetic development to design small-molecule therapeutics, closed a $53m Series A financing.
The round was led by Coatue and Catalio Capital Management, with participation from OrbiMed and Sequoia Capital as well as existing investors Nexus Ventures and Freeflow. As part of the funding, Aaron Weiner, Managing Director and Head of Healthcare at Coatue, and R. Jacob Vogelstein, Ph.D., Co-Founder and Managing Partner of Catalio, joined Entos’ Board of Directors that includes Tom Miller, Co-Founder and Chief Executive Officer, Fred Manby, Co-Founder and Chief Technology Officer, and Naren Gupta, Co-Founder and Managing Director of Nexus Venture Partners.
The company intends to use the funds to accelerate the development of its OrbNet AI-platform, including integrating the technology with robotic synthesis and high-throughput experimentation and to further strengthen its science and engineering talent.
Founded in 2019 by Tom Miller, Chief Executive Officer, Tim Cernak, Chief Scientific Officer, and Sarah Trice, Chief Operating Officer, Entos is a therapeutic discovery company which leverages OrbNet, its platform combining AI-driven technology and automated synthetic development to design small-molecule therapeutics. Through OrbNet, the company has already achieved customer traction with a portfolio of partnerships with industry leaders in pharmaceuticals, chemicals and materials.